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Abstract
Background: Development of tuberculosis (TB) is determined by various risk factors and the interactions of
temporal and spatial distributions. The aim of this study was to identify the most salient risk factors for TB disease
as well as multidrug resistant TB (MDR-TB) at the oblast (provincial) level in Kazakhstan.
Methods: Correlational and descriptive analyses were conducted at the oblast and national level using data
provided by the country’s National Institute of Geography (NIG) and the National Tuberculosis Program (NTP).
Reported incident case notification rates (CNRs) and prevalence vary by oblast, thus the study investigated which
determinants contributed to this regional variation and compared burdens among oblasts.
Results: The results showed that while tuberculosis CNRs decreased over the study period, MDR-TB conversely
increased. Two oblasts -Atyrauskaya and Mangystauskaya - presented especially significant anomalies with large
decreases in TB incident CNRs coupled with comparatively large increases in MDR-TB incident CNRs.
Conclusion: Understanding the distribution of TB and MDR-TB cases and associated risk factors, especially the
“unknown risk factor” categorization points to the need for future research.
Keywords: Tuberculosis, Case notification rate (CNR), Prevalence, Risk factors, MDR-TB, Kazakhstan, Spatial
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Background
Despite World Health Organization’s (WHO) recent re-
port describing a decline in tuberculosis (TB) morbidity
and mortality, the disease remains an acute threat to
global public health [1]. The increase in tuberculosis
case notification rates (CNRs) across much of the
former Soviet Union (FSU) since its dissolution has
been well-documented [2,3]. Following the break-up of
the Soviet Union, Kazakhstan experienced a dramatic
increase in tuberculosis infections. Incidence rates
reported to the WHO in 1995 (135/100,000 population),
2000 (196/100,000), and 2004 (223/100,000) chronicled
this increase, which spurred the country’s public health
sector to introduce new approaches to tuberculosis con-
trol [4]. Starting in 1998, Kazakhstan’s Ministry of Health
(MoH) began implementing Directly Observed Therapy
Short Course (DOTS) through the then newly created
National Tuberculosis Program (NTP), which continues
to oversee TB care and treatment in the country today.
In several FSU republics including Kazakhstan, multi-
drug resistant forms of the disease increasingly threaten
TB control efforts [5,6]. The NTP provides free TB treat-
ment for its residents via a centralized network of TB
dispensaries, hospitals, and polyclinics. While polyclinics
may perform tentative TB diagnosis and later serve as
local sites for continued treatment, they initially refer all
suspected cases to NTP facilities [7]. The NTP system
currently consists of 315 microscopy laboratories and
funding was recently allocated to the network to im-
prove diagnostic capacities. In the first quarter of 2012,
the NTP reported that Kazakhstan was the only Central
Asian republic where all of the oblasts had the capacity
to perform drug resistance testing, citing a testing rate
of 98.2% of new TB cases and 98.9% of retreatment cases
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covered by DOTS [8]. However, TB drug resistance test-
ing of all cases has not been fully achieved within
Kazakhstan’s prison system. Hein genotyping analysis is
currently being piloted in 10 out of 14 oblasts. Despite
these advances in TB control efforts, in practice, TB
diagnosis is often based on x-ray rather than bacterio-
logical analysis.
TB incidence peaked in Kazakhstan in 2003 and 2004,
since then the NTP has attained some success in
restraining further increases; however, MDR-TB presents
a growing challenge to controlling TB. The WHO
reports that 14% (range 11-18%) of all newly diagnosed
TB cases in Kazakhstan are multidrug resistant. Among
retreatment cases, 45% test positive for MDR-TB [4].
Since such statistics were first recorded in 1998, the
country’s success rates for treatment of new TB cases
have consistently fallen below the WHO-recommended
≥85% cure rate. In fact, success rates declined to 62% in
2009 after achieving an earlier high of 79% [9,10]. The
problem is compounded by high MDR-TB rates in pris-
ons, where CNRs may be five times higher than in the
general population [11].
Interest in the social, economic, and environmental
determinants of TB has grown as CNRs have risen dur-
ing the past two decades. The contextual milieu in
which individuals live and work is critical to understand-
ing and stemming the disease [12]. A literature review
identified several global risk factors for TB. Individual
risks include age, sex, smoking, alcoholism, diabetes,
HIV status, marital status, ethnicity, homelessness, incar-
ceration, drug use, and migrant status [13-18]. Socioeco-
nomic and environmental risk factors take into account
deprivation, financial insecurity, and housing conditions.
[13,14,19] While these risk factors may play a role in in-
creasing Kazakhstan’s overall TB burden and intensifying
MDR-TB, they have not been adequately examined.
This study presents the first comprehensive descrip-
tion of the spatial and temporal burden of TB disease
constructed from data obtained from the Kazakhstani
national TB surveillance system. Study findings identify
salient risk factors for TB disease as well as MDR-TB at
the oblast (provincial) level in Kazakhstan. Reported in-
cident CNRs and prevalence vary by oblast, thus the
study investigated which determinants contribute to this
regional variation. By analyzing aggregate and individual
case records provided by the country’s National Institute
of Geography and the National Tuberculosis Program,
we compared burdens among oblasts and identified sig-
nificant risk determinants.
Methods
Data Source
Surveillance data from the National Tuberculosis
Program (NTP) and the National Institute of Geography
(NIG) were obtained for the years 2006 through 2010.
NTP surveillance data included all new tuberculosis
cases diagnosed and reported to the NTP from January
1, 2006 through December 31, 2010 and tuberculosis
and MDR-TB national incidence and prevalence (2006 –
2010) estimates. The NIG provided surveillance data on
oblast population estimates (2006 – 2010). De-identified
data was obtained in Microsoft Access 2010, Excel 2010,
and Word 1997–2003. Standard data security and man-
agement procedures were followed to ensure the highest
level of data safety. The study was conducted under a
protocol approved by the Institutional Review Boards of
Columbia University and Nazarbayev University.
As described above, the NTP provides free diagnosis
and treatment of TB and MDR-TB. Kazakhstan’s labora-
tory network holds a Class B rating by the WHO [20].
Routine testing provides data on TB cases, with positive
cultures available for a minimum of 35% of notified
cases. Drug susceptibility is tested for a minimum of
50% of positive culture cases. The entire notification
process delivers a “moderately high degree of representa-
tiveness” of the MDR-TB national burden [21]. The
NTP defines a TB case as any suspected TB case that
has even one positive smear, or a negative smear exam-
ination and a clinical and radiographic presentation con-
sistent with TB that responds to drug treatment [20].
MDR-TB is defined as resistance to both isoniazid and
rifampicin. The surveillance data utilized for the current
analysis does not differentiate between new and retreat-
ment MDR-TB cases.
Individual risk factors recorded by the NTP and
included in this analysis are alcohol use, child or youth
from a vulnerable group, known diabetes diagnosis, his-
tory of illicit drug use, incarceration history within the
past two years, migrant status, non-regular uptake of
anti-tuberculosis medication (less relevant for new
cases), prison system staff member, recent mother (hav-
ing given birth within one year of diagnosis), registered
contact of a TB or MDR-TB case, TB health care staff
member, and a category listed as “unknown individual
risk factors.” Additionally, categories for employment
status included currently incarcerated, detainee, farmer,
officer, pensioner, child or youth, prison medical staff,
self-employed, student, TB clinic medical staff, worker,
unemployed, or other. Individual level data was not
available for geocoding beyond the rayon (community)
level; therefore, analysis on residential related variables
could not be conducted.
Methods
Descriptive statistical analyses on the oblast and national
levels were conducted in Microsoft Excel 2010 and SAS
9.2. National and oblast level incident CNRs and preva-
lence data presented here were reported directly from
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the NTP and are assumed to have an underlying Poisson
distribution [21,22]. Poisson ratio comparisons for sta-
tistically significant associations were conducted on
national and oblast level incident CNR and prevalence
estimates to test for statistically significant change
(p < 0.05) [22,23]. Pearson correlation coefficients were
calculated between total cases with known characteris-
tics of incident cases and total new cases registered, by
year (p < 0.05) [24,25].
Results
Incident CNR and prevalence of TB and MDR-TB
Table 1 presents the incident CNR and prevalence of
TB and MDR-TB in Kazakhstan from 2007 to 2010 as
reported by the NTP. CNRs of TB and MDR-TB are
presented by oblast. In 2007 the CNR of tuberculosis
was reported as 126.4 cases per 100,000 and in 2010
that figure significantly declined to 95.3 cases per
100,000 (p = 0.02). Nine out of the fourteen oblasts in
Table 1 Tuberculosis prevalence and case notification rate in Kazakhstan from 2007 – 2010†
Variable 2007 2008 2009 2010 Change
2007 - 2010
CNR of tuberculosis (per 100,000 population) 126.4 125.5 105.3 95.3 p = 0.02
Almatynskaya oblast 53.7 55.7 50.5 49.8 p = 0.35
Akmolinskaya oblast 85.6 92.1 82.5 62.6 p = 0.03
Aktubinskaya oblast 138.2 122.1 96.8 87.1 p < 0.01
Atyrauskaya oblast 168.1 160.9 124.4 120.8 p < 0.01
East-Kazakhstan oblast 129.4 128.5 121.0 122.1 p = 0.32
Karagandinskaya oblast 129.5 114.2 96.6 89.3 p < 0.01
Kostanayskaya oblast 141.8 143.8 114.0 108.1 p = 0.02
Kyzylordinskaya oblast 167.5 155.8 120.6 110.5 p < 0.01
Mangystauskaya oblast 155.7 157.3 123.6 111.8 p < 0.01
North-Kazakhstanskaya oblast 154.8 152.9 118.5 96.1 p < 0.01
Pavlodarskaya oblast 141.9 138.4 111.2 97.0 p < 0.01
South-Kazakhstanskaya oblast 83.7 87.2 77.4 77.3 p = 0.31
West-Kazakhstan oblast 109.6 137.3 106.0 94.3 p = 0.14
Zhambylskaya oblast 100.4 115.3 89.4 86.4 p = 0.15
Prevalence of tuberculosis (per 100,000 population) 283.6 201.4 180 166.3 p < 0.01
CNR of multidrug resistant tuberculosis
(per 100,000 population)
5.8 8.5 8.5 10.5 p = 0.12
Almatynskaya oblast 4.1 7.7 7.8 13.1 p = 0.02
Akmolinskaya oblast 3.2 2.2 7.2 7.0 p = 0.12
Aktubinskaya oblast 3.1 12.0 10.5 8.7 p = 0.05
Atyrauskaya oblast 13.2 18.5 16.7 22.8 p = 0.05
East-Kazakhstan oblast 8.0 11.2 13.7 15.2 p = 0.07
Karagandinskaya oblast 6.0 6.9 6.3 11.3 p = 0.10
Kostanayskaya oblast 5.2 4.4 12.5 4.0 p = 0.35
Kyzylordinskaya oblast 5.1 13.1 2.7 15.4 p = 0.01
Mangystauskaya oblast 15.5 16.8 15.1 11.1 p = 0.20
North-Kazakhstanskaya oblast 5.9 13.2 11.3 12.0 p = 0.07
Pavlodarskaya oblast 6.6 13.3 7.2 9.8 p = 0.21
South-Kazakhstanskaya oblast 5.0 1.7 2.4 4.3 p = 0.41
West-Kazakhstan oblast 7.2 10.0 9.3 13.7 p = 0.08
Zhambylskaya oblast 6.2 15.4 10.4 13.1 p = 0.06
Prevalence of multidrug resistant tuberculosis
(per 100,000 population)
54.4 49.8 52.9 61.6 p = 0.25
† NTP Center Statistics.
Terlikbayeva et al. BMC Infectious Diseases 2012, 12:262 Page 3 of 9
http://www.biomedcentral.com/1471-2334/12/262
Kazakhstan observed a statistically significant decrease in
CNR of tuberculosis from 2007 to 2010 (Akmolinskaya,
Aktubinskaya, Atyrauskaya, Karagandinskaya, Kosta-
nayskaya, Kyzylordinskaya, Mangystauskaya, North-
Kazakhstanskaya, and Pavlodarskaya oblasts). The
national prevalence similarly significantly decreased
from 283.6 cases per 100,000 in 2007 to 166.3 cases
per 100,000 in 2010 (p < 0.01).
National MDR-TB incident CNR has conversely
increased over the same time period, from 5.8 cases
per 100,000 in 2007 to 10.5 cases per 100,000 in
2010 (p = 0.12). Four out of fourteen oblasts observed
a statistically significant change in MDR-TB incident
CNR (Almatynskaya, Aktubinskaya, Atyrauskaya, and
Kyzylordinskaya oblasts). Almatynskaya oblast was one
of the four oblasts that did not experience a statisti-
cally significant decrease in TB CNR over the same
time period. National MDR-TB prevalence increased
from 54.4 cases per 100,000 in 2007 to 61.6 cases per
100,000 in 2010 (p = 0.25).
Nationally aggregated TB and MDR-TB CNRs and
prevalence data was available for 2006. Its inclusion in
the analysis supports the observed decrease of TB CNR
coupled with the increase in MDR-TB CNR. Figure 1A
and 1B compare TB and MDR-TB CNRs and preva-
lence from 2006 to 2010. While statistically significant
decreases in tuberculosis CNR (p < 0.01) and preva-
lence (p < 0.01) have been achieved, the MDR-TB CNR
(p < 0.04) and prevalence (p = 0.22) burdens have
increased.
Tuberculosis and MDR-TB have different spatial dis-
tributions within Kazakhstan (see Figures 2A-Figure 3B).
In 2010, Atyrauskaya and East-Kazakhstan oblasts had
the highest CNRs of tuberculosis with Almatynskaya and
Akmolinskaya oblasts reporting the lowest CNRs. From
2007 – 2010 North-Kazakhstan and Kyzylordinskaya
oblasts reported the greatest percentage decrease in
CNRs (both p < 0.01). For MDR-TB in 2010, again
Atyrauskaya and East-Kazakhstan oblasts were in the
highest category of CNRs in the country, with Atyrauskaya
Figure 1 A: Tuberculosis and multidrug resistant tuberculosis CNRs in Kazakhstan from 2006 – 2010. Tuberculosis CNR decrease from
2006 to 2010 was statistically significant on a p = 0.05 level. B: Tuberculosis and multidrug resistant tuberculosis prevalence in Kazakhstan from
2006 – 2010. Tuberculosis prevalence decrease from 2006 to 2010 was statistically significant on a p = 0.05 level.
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oblast reporting the largest percentage increase in MDR-
TB CNR (p = 0.05). Kostanayskaya and South-Kazakhstan
oblasts reported the lowest CNRs of MDR-TB in the coun-
try with Kostanayskaya also having the lowest percentage
increase in CNR (p = 0.35).
Characteristics of new TB cases in Kazakhstan
Table 2 summarizes key characteristics of tuberculosis
cases from the NTP registry. Risk factors collected at
diagnosis include whether or not the case is a registered
contact of another tuberculosis or MDR-TB case (5%
and <1% in 2010 respectively), has diabetes (2%, 2010),
reports illicit drug or alcohol use (<1% and 2% in 2010
respectively), was incarcerated within the past two years
(2%, 2010), is a child or youth from a vulnerable group
(1%, 2010), is a staff member in a TB treatment unit or
in a prison (<1% for both, 2010), is a recent mother
(2%), had non-regular uptake of anti-tuberculosis medi-
cation (<1%, 2010), or is a migrant (3%, 2010). New
cases in this dataset are first time cases referred to the
NTP center at diagnosis. Based on available data, it is
impossible to determine if cases labeled as non-regular
uptake of anti-tuberculosis medication are done so be-
cause they are treatment failures, retreatment cases, or
have a historic lack of adherence episode. Most illus-
trative is that the NTP consistently reports that over
85% of the cases referred indicate that risk factors
are “unknown” at diagnosis. The categorization of
“unknown risk factor” requires further exploration in
subsequent studies. Considering the employment status
of notified cases in 2010, most were unemployed (52%),
with workers as the next highest category (14%). Other
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Figure 2 A: Spatial distribution of tuberculosis case notification rate in Kazakhstan 2010. B: Spatial distribution of tuberculosis case
notification rate change in Kazakhstan from 2007 – 2010. Tuberculosis CNR change was calculated by finding the difference between the 2010
CNR and the 2007 CNR. All oblasts observed a reduction in incidence, and the more negative represent those areas that experienced a larger
decrease compared to those that are less negative. Oblasts in the three lightest range and some of the fourth experienced a statistically
significant change on the p = 0.05 level.
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employment categories were represented by less than
10% of respondents.
Of the 26 characteristics collected, seven were sig-
nificantly correlated with new TB case notification.
These included being a registered contact of a TB case
(p = 0.02), being incarcerated within the past two years
(p = 0.03), having unknown risk factors (p = 0.03),
self-identifying as an officer (p = 0.05), self-identifying
as a worker (p = 0.05), self-identifying as unemployed
(p = 0.04), and self-identifying as a detainee (p = 0.03).
Discussion
Kazakhstan has a high rate of tuberculosis overall, and
one of the highest rates of MDR-TB in the world. This
study provides a comprehensive description of the epi-
demiology of tuberculosis and MDR-TB in this rapidly
developing Central Asian nation. The findings demon-
strate that although the overall CNR of tuberculosis has
declined significantly over the past five years, the CNR
of MDR-TB has risen. It is probable that there is both
under- and over-diagnosis of TB cases in Kazakhstan be-
cause a substantial proportion of cases are identified
clinically and unconfirmed by culture. Some of these
cases may represent prior, healed TB with exacerbations
of bronchiectasis, for example. In addition, it is likely
that the lack of routine access to culture and drug sus-
ceptibility testing may result in considerable under-
diagnosis of tuberculosis cases overall, and perhaps
differential under-diagnosis of drug-resistance. It is quite
probable that a low CNR for MDR-TB represents under-
diagnosis, and this under-diagnosis is contributing to the
spread of MDR-TB in several oblasts. Rapid diagnosis of
4
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Figure 3 A: Spatial distribution of MDR-TB case notification rate in Kazakhstan 2010. B: Spatial distribution of tuberculosis case notification
rate change in Kazakhstan from 2006 – 2010. Multidrug resistant tuberculosis CNR percentage change was calculated by finding the difference
between the 2010 and 2006 CNRs. All oblasts experienced an increase in MDR-TB CNR, and the more positive represent those areas that
experienced a larger increase as compared to those that are smaller. More than half the oblasts in the country experienced a statistically
significant change on the p = 0.05 level.
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TB and drug susceptibility testing using the WHO-
recommended Cepheid GenExpert is expected in
Kazakhstan in late 2012. Cepheid GenExpert should
improve detection and treatment of MDR-TB cases.
The national data on CNRs and MDR-TB are not uni-
formly distributed; Atyrauskaya and Mangystauskaya
oblasts present anomalies with large decreases in TB
CNRs coupled with comparatively large increases in
MDR-TB CNRs. The lack of uniformity in distribution
may result from differential socio-environmental factors
and a lack of access to treatment. After the FSU collapse,
access to anti-tuberculosis chemotherapy became limited
and sporadic, and supervision and surveillance of
patients with tuberculosis was inadequate. These factors
undoubtedly contributed to the proliferation of MDR-
TB cases in Russia and FSU republics that is apparent
today. Understanding the reasons for the differential
socio-environmental factors and lack of access to treat-
ment will be critical to developing effective strategies for
controlling TB in Kazakhstan and limiting the prolifera-
tion of MDR strains of tuberculosis.
Kazakhstan’s national TB control program classified a
high percentage of patients (83% – 87% throughout the
study period) as being without identified risk factors for
tuberculosis. Such risk factors may be related to un-
detected TB transmission in the community or in
Table 2 Kazakhstan tuberculosis new case characteristics†
Variable 2007 n (%) 2008 n (%) 2009 n (%) 2010 n (%)
Total new cases registered 18,290 19,311 16,608 15,617
Risk factors
Alcohol use 787 (4%) 639 (3%) 398 (2%) 346 (2%)
Child or youth from vulnerable group 362 (2%) 271 (1%) 237 (1%) 175 (1%)
Diabetes 252 (1%) 284 (1%) 263 (2%) 246 (2%)
Drug use 58 51 47 44
Incarcerated within past 2 years* 70 74 53 52
Migrant 174 (1%) 922 (5%) 444 (3%) 417 (3%)
Non-regular uptake of anti-tuberculosis medication 14 43 23 24
Prison system staff member 31 28 21 18
Recent mother (birth within 1 year) 204 (1%) 397 (2%) 330 (2%) 323 (2%)
Registered contact of a multidrug
resistant tuberculosis case
28 62 64 72
Registered contact of a tuberculosis case* 928 (5%) 1034 (5%) 862 (5%) 739 (5%)
Tuberculosis health care staff member 1 1 0 3
Unknown risk factor* 15,883 (87%) 15,953 (83%) 14,173 (85%) 13,451 (86%)
Socio-economic indicators
Employment status
Currently incarcerated 6 8 5 11
Detainee* 0 0 2 3
Farmer 8 7 8 4
Officer* 1,365 (7%) 1,406 (7%) 1,246 (8%) 1,048 (7%)
Other 1,006 (6%) 1,083 (6%) 748 (5%) 832 (5%)
Pensioner 893 (5%) 994 (5%) 816 (5%) 868 (6%)
Pre-school child 45 160 (1%) 140 (1%) 141 (1%)
Prison medical staff 13 128 (1%) 141 (1%) 106 (1%)
Self-employed 465 (3%) 139 (1%) 92 (1%) 84 (1%)
Student 1,566 (9%) or 975 (5%) 1,522 (8%) or 1,066 (6%) 1,401 (8%) or 967 (6%) 1,293 (8%) or 843 (5%)
Tuberculosis clinic medical staff 13 32 35 30
Unemployed* 9,029 (49%) 10,054 (52%) 8,655 (52%) 8,088 (52%)
Worker* 2,707 (15%) 2,681 (14%) 2,302 (14%) 2,234 (14%)
† NTP registry, percentages are not presented for variables representing less than 1% of cases.
* Variable is statistically correlated with number of new cases of TB at a p = 0.05 level.
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institutional settings. Many instances of nosocomial
transmission of tuberculosis, especially of MDR-TB, have
been reported around the world, including diverse
locations such as New York and Johannesburg, and it
is possible that a similar situation has occurred in
Kazakhstan. It is also possible that some MDR strains
currently present in Kazakhstan are particularly viru-
lent and capable of generating a large number of sec-
ondary cases before a new index case is diagnosed.
Risks may also be related to selection of the single
drug resistant strains induced by previous treatments.
An influx of migrant workers has been attracted to the
country because of its rapid development. Migrants typ-
ically are at increased risk of tuberculosis as they have
limited access to health care services, including anti-
tuberculosis chemotherapy, and reside in crowded con-
ditions that favor the rapid transmission of tuberculosis.
It is also possible that immigrants are entering Kazakhstan
knowing that they have MDR-TB because they perceive
that services and treatment are available that are not
attainable in their home countries. This could lead to a
rise in MDR-TB cases that outpaces the rise in drug-
susceptible cases. This explanation is supported by the
large increases in MDR-TB prevalence reported in the two
oblasts (Atyrauskaya and Mangystauskaya) with the highest
immigration rates. Most migrants come to these areas
from other high TB incidence Central Asian countries.
Previous studies have reported higher risks for MDR-TB
in foreign-born individuals [25]. Future studies need to
investigate the link between migration and MDR-TB
CNRs, taking into account previous treatment.
Another possibility for increasing MDR-TB CNRs is
that although DOTS is available for patients reported to
the NTP, delayed detection of drug resistance among
clinically and microbiologically confirmed cases of tuber-
culosis limits DOTS effectiveness. Patients may not be
receiving ideal therapy in a timely fashion. Use of the
Cepheid GenExpert system could ameliorate this situ-
ation. GenExpert will be introduced in four regions of
Kazakhstan in 2012 with the help of a USAID-funded
pilot project. The sustainability of the GenExpert system
long-term is yet to be determined. Furthermore, if cases
of MDR-TB are not promptly diagnosed, nosocomial
transmission of MDR-TB could be playing a substantial
role in the rising MDR-TB rates, particularly as the prac-
tice in Kazakhstan is to treat all TB patients with pro-
longed periods of hospitalization.
Positive HIV/AIDS status is an important risk factor
related to increasing MDR-TB transmission rates.
Kazakhstan, along with other eastern European and
Central Asian countries, belongs to the region with the
fastest growing HIV epidemic in the world. Several
studies noted that HIV-infected patients with TB develop
drug-resistance, particularly to rifampicin, in response to
erratic administration of chemotherapy [26,27]. This could
lead to drug-susceptible cases being converted to drug-
resistant cases, even without increasing the total num-
ber of TB cases overall [28,29]. Further studies are required,
and one is currently underway, to understand the rela-
tionship between HIV status and drug-susceptibility in
Kazakhstan.
Other aspects of the current study deserve particular
comment. Compared with previous research, recent in-
carceration or employment in a prison was not highly
represented as a reported risk factor for new TB cases.
This could represent a true improvement in control and
treatment programs within the prison system or an
artifact of the reporting process.
Limitations
The study findings represent an analysis of all the data
reported to the NTP. However, through a detailed re-
view and analysis of the data provided for this study,
various inconsistencies in reporting, variable definitions,
and collection procedures were uncovered when com-
paring NTP data with other published documents. The
data might not accurately reflect the diverse collection
and reporting methods currently functioning across the
country. Divergent MDR-TB CNRs could be reflective of
the quality of the NTP or an artifact of diverse testing
practices. Atyrauskaya and Mangystauskaya could report
higher incidence of MDR-TB because the oblasts may
have more financial resources available and impetus
to test suspected TB cases than areas such as South-
Kazakhstan. These inconsistencies are being investi-
gated through continued collaboration with our study
partners at the NTP and NIG. Accurate surveillance
and reporting is critical to controlling tuberculosis in
any locale.
Conclusion
In conclusion, this study expands current knowledge of
the epidemiology of tuberculosis in Kazakhstan. Not-
withstanding the limitations detailed above, understand-
ing the distribution of TB and MDR-TB cases and
associated risk factors provides context for future stud-
ies. The continuing rise of MDR cases in Kazakhstan
and other countries in the FSU should be considered a
global health emergency. The findings presented here
provide a roadmap to further investigations that can lead
to the underlying causes of the problem. Understanding
the ‘unknown risk factor’ categorization and reporting
practices across the country are two ideal starting points
for further research that will yield benefits to the entire
public health system in Kazakhstan.
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